Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04013516
Other study ID # 004
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 12, 2017
Est. completion date September 11, 2017

Study information

Verified date July 2019
Source IDinsight
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria. The purpose of the experiment is to help New Incentives (NI) determine the optimal size of the incentive as they scale to the North West region of Nigeria.


Recruitment information / eligibility

Status Completed
Enrollment 1088
Est. completion date September 11, 2017
Est. primary completion date September 11, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Months and older
Eligibility Inclusion Criteria:

- Caregiver and infant registered with the New Incentives program

- The infant was nine months or older at the start of the study (note there was no upper age limit as New Incentives only began enrolling infants in October 2016)

- Infant had received at least one previous conditional cash transfer for immunization at an All Babies are Equal Initiative clinic,

- Infant had received their Penta-3 vaccine.

- The caregiver had provided a phone number (either a personal number or a number of someone who can reach them) during registration.

Exclusion Criteria:

- Infant had already received a measles vaccine

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cash Incentive
During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
Call
A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).

Locations

Country Name City State
Nigeria All Babies are Equal Initiative (New Incentives) Abuja Federal Capital Territory

Sponsors (2)

Lead Sponsor Collaborator
IDinsight GiveWell

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measles Vaccination Coverage Rate The outcome of interest is the measles coverage rate among the eligible randomized infants. Coverage is measured using the measles vaccination information recorded on the child's health card. The child health card information was immediately entered into the New Incentives' database by their field staff when they disbursed the cash incentives at program clinics. Information from the New Incentives' database was used for the analysis. We assessed whether eligible infants received measles vaccination at any time during the 4 month study period. Children were a minimum of 9 months at the beginning of the study and a maximum of 7 years at the end of the study.
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4